董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William White | 男 | Director | 53 | 未披露 | 未持股 | 2026-07-28 |
| Mona Ashiya | 女 | Director | 57 | 未披露 | 未持股 | 2026-07-28 |
| Bill Lundberg | 男 | Chairman of the Board and Director | 62 | 未披露 | 未持股 | 2026-07-28 |
| Peter Silverman | 男 | Director | 48 | 未披露 | 未持股 | 2026-07-28 |
| Rebecca Frey | 女 | Chief Executive Officer and Director and President | 52 | 未披露 | 未持股 | 2026-07-28 |
| Steven Hoerter | 男 | Director | 55 | 未披露 | 未持股 | 2026-07-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Ryder | 男 | Chief Medical Officer | 75 | 未披露 | 未持股 | 2026-07-28 |
| Tyler Zeronda | 男 | Chief Financial Officer | 40 | 未披露 | 未持股 | 2026-07-28 |
| Rebecca Frey | 女 | Chief Executive Officer and Director and President | 52 | 未披露 | 未持股 | 2026-07-28 |
| Rachael Alford | 女 | Chief Operating Officer | 53 | 未披露 | 未持股 | 2026-07-28 |
| Lori Payton | 女 | Chief Development Officer | 60 | 未披露 | 未持股 | 2026-07-28 |
董事简历
中英对照 | 中文 | 英文- William White
-
自2019年4月以来，William White一直担任我们的执行Vice President，首席财务官和企业发展主管。在加入我们公司之前，怀特先生于2017年9月至2019年3月担任德意志银行董事总经理兼美国生命科学投资银行业务主管。在担任该职位之前，怀特先生于2006年5月至2017年9月担任花旗集团梦百合投资银行业务董事总经理。此前，他曾于2004年4月至2006年3月担任高盛（Goldman，Sachs&Co.）梦百合投资银行业务Vice President。White先生在普林斯顿大学（Princeton University）获得A.B.，在哈佛大学（Harvard University）获得M.P.，在哥伦比亚大学（Columbia University）获得J.D.。
William White has served as a member of Yarrow's board of directors since April 2026. Mr. White served as the Executive Vice President, Chief Financial Officer and Head of Corporate Development and Treasurer at Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, from April 2019 until its acquisition by Novo Nordisk in December 2025. Before joining Akero, Mr. White served as a Managing Director and Head of US Life Sciences Investment Banking at Deutsche Bank AG, an investment banking company, from September 2017 until March 2019. Prior to that position, Mr. White was a Managing Director in Healthcare Investment Banking at Citigroup Inc., a multinational investment bank and financial services company, from May 2006 until September 2017. Previously, he served as an associate and later as a Vice President in Healthcare Investment Banking at Goldman, Sachs & Co., a global financial institution, from November 2000 to March 2006. Mr. White has served as a member of the board of directors of Disc Medicine, Inc. (Nasdaq: IRON) since December 2020 and previously served on the board of directors of Ventyx Biosciences, Inc. (formerly, Nasdaq: VTYX) from May 2021 until its acquisition by Eli Lilly and Company in March 2026. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University. - 自2019年4月以来，William White一直担任我们的执行Vice President，首席财务官和企业发展主管。在加入我们公司之前，怀特先生于2017年9月至2019年3月担任德意志银行董事总经理兼美国生命科学投资银行业务主管。在担任该职位之前，怀特先生于2006年5月至2017年9月担任花旗集团梦百合投资银行业务董事总经理。此前，他曾于2004年4月至2006年3月担任高盛（Goldman，Sachs&Co.）梦百合投资银行业务Vice President。White先生在普林斯顿大学（Princeton University）获得A.B.，在哈佛大学（Harvard University）获得M.P.，在哥伦比亚大学（Columbia University）获得J.D.。
- William White has served as a member of Yarrow's board of directors since April 2026. Mr. White served as the Executive Vice President, Chief Financial Officer and Head of Corporate Development and Treasurer at Akero Therapeutics, Inc. (Nasdaq: AKRO), a biotechnology company, from April 2019 until its acquisition by Novo Nordisk in December 2025. Before joining Akero, Mr. White served as a Managing Director and Head of US Life Sciences Investment Banking at Deutsche Bank AG, an investment banking company, from September 2017 until March 2019. Prior to that position, Mr. White was a Managing Director in Healthcare Investment Banking at Citigroup Inc., a multinational investment bank and financial services company, from May 2006 until September 2017. Previously, he served as an associate and later as a Vice President in Healthcare Investment Banking at Goldman, Sachs & Co., a global financial institution, from November 2000 to March 2006. Mr. White has served as a member of the board of directors of Disc Medicine, Inc. (Nasdaq: IRON) since December 2020 and previously served on the board of directors of Ventyx Biosciences, Inc. (formerly, Nasdaq: VTYX) from May 2021 until its acquisition by Eli Lilly and Company in March 2026. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University.
- Mona Ashiya
-
Mona Ashiya目前是投资公司OrbiMed Advisors LLC的成员，自2010年以来，她在该公司担任过各种职责不断增加的角色。她目前在Disc Medicine，Inc.（纳斯达克：IRON）和多家私营公司的董事会任职。Ashiya博士在加州大学伯克利分校获得学士学位，在匹兹堡大学获得细胞、分子和发育生物学博士学位。
Mona Ashiya has served as a member of the Yarrow board of directors since December 2025. Dr. Ashiya is currently a Member at OrbiMed Advisors LLC, an investment firm, where she has served in various roles of increasing responsibility since 2010. She currently serves on the boards of directors of Shattuck Labs, Inc. (Nasdaq: STTK) and several private companies. Dr. Ashiya previously served on the boards of directors of Disc Medicine, Inc. (Nasdaq: IRON) from September 2021 to October 2025 and Sierra Oncology, Inc. (formerly, Nasdaq: SRRA) from November 2019 to July 2022. Dr. Ashiya received her B.A. from the University of California, Berkeley and her Ph.D. in Cellular, Molecular and Developmental Biology from the University of Pittsburgh. - Mona Ashiya目前是投资公司OrbiMed Advisors LLC的成员，自2010年以来，她在该公司担任过各种职责不断增加的角色。她目前在Disc Medicine，Inc.（纳斯达克：IRON）和多家私营公司的董事会任职。Ashiya博士在加州大学伯克利分校获得学士学位，在匹兹堡大学获得细胞、分子和发育生物学博士学位。
- Mona Ashiya has served as a member of the Yarrow board of directors since December 2025. Dr. Ashiya is currently a Member at OrbiMed Advisors LLC, an investment firm, where she has served in various roles of increasing responsibility since 2010. She currently serves on the boards of directors of Shattuck Labs, Inc. (Nasdaq: STTK) and several private companies. Dr. Ashiya previously served on the boards of directors of Disc Medicine, Inc. (Nasdaq: IRON) from September 2021 to October 2025 and Sierra Oncology, Inc. (formerly, Nasdaq: SRRA) from November 2019 to July 2022. Dr. Ashiya received her B.A. from the University of California, Berkeley and her Ph.D. in Cellular, Molecular and Developmental Biology from the University of Pittsburgh.
- Bill Lundberg
-
Bill Lundberg，是Merus的首席执行官、总裁、首席财务官兼董事。在担任该职务之前，Lundberg博士于2015年1月至2018年2月期间在生物技术公司CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）担任首席科学官。Lundberg博士还曾于2011年2月至2015年1月在亚力兄制药公司担任副总裁兼过渡医学负责人。在担任该职位之前，Lundberg博士曾担任生物技术公司Taligen Therapeutics，Inc.的董事兼首席医疗官，该公司于2011年被Alexion收购。在加入Taligen之前，他曾在Xanthus/Antisoma、Wyeth（现辉瑞）、Genzyme担任多个临床药物开发和医疗事务高级职务。伦德伯格博士目前在上市的生命科学公司Vor Biopharma（纳斯达克股票代码：VOR）和Merus的董事会任职。伦德伯格博士拥有斯坦福大学的医学博士学位和马萨诸塞大学的工商管理硕士学位。
Bill Lundberg has served as Chair of Yarrow's board of directors since April 2026. Since August 2018, Dr. Lundberg has served as a Partner at Cold Spring Partners, LLC, an investment firm. Dr. Lundberg previously served as President and Chief Executive Officer of Merus N.V. (formerly, Nasdaq: MRUS), a biotechnology company, from December 2019 until Merus was acquired by Genmab A/S in December 2025, and as the Principal Financial Officer of Merus from December 2019 to June 2023. Dr. Lundberg also served as a member of the board of directors of Merus from June 2019 to December 2025. Prior to joining Merus, he served as Chief Scientific Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biotechnology company, from January 2015 to February 2018. From February 2011 to January 2015, Dr. Lundberg served as Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company. Prior to that, he served as Director and Chief Medical Officer of Taligen Therapeutics, Inc., a biotechnology company acquired by Alexion in 2011. Dr. Lundberg held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus Pharmaceuticals, Inc. (acquired by Antisoma plc), Wyeth (acquired by Pfizer Inc.), and Genzyme Corporation (formerly, Nasdaq: GENZ). Dr. Lundberg has served as a member of the board of directors of Q32 Bio Inc. (Nasdaq: QTTB) since September 2017 and previously served on the board of directors of Vor Biopharma Inc. (Nasdaq: VOR) from July 2019 to July 2025. Dr. Lundberg received his M.D. from Stanford University and his M.B.A. from the University of Massachusetts. He completed post doctoral training at the Whitehead Institute/MIT and clinical training in Medicine and Medical Oncology at Harvard Medical School and the Dana Farber Cancer Institute. - Bill Lundberg，是Merus的首席执行官、总裁、首席财务官兼董事。在担任该职务之前，Lundberg博士于2015年1月至2018年2月期间在生物技术公司CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）担任首席科学官。Lundberg博士还曾于2011年2月至2015年1月在亚力兄制药公司担任副总裁兼过渡医学负责人。在担任该职位之前，Lundberg博士曾担任生物技术公司Taligen Therapeutics，Inc.的董事兼首席医疗官，该公司于2011年被Alexion收购。在加入Taligen之前，他曾在Xanthus/Antisoma、Wyeth（现辉瑞）、Genzyme担任多个临床药物开发和医疗事务高级职务。伦德伯格博士目前在上市的生命科学公司Vor Biopharma（纳斯达克股票代码：VOR）和Merus的董事会任职。伦德伯格博士拥有斯坦福大学的医学博士学位和马萨诸塞大学的工商管理硕士学位。
- Bill Lundberg has served as Chair of Yarrow's board of directors since April 2026. Since August 2018, Dr. Lundberg has served as a Partner at Cold Spring Partners, LLC, an investment firm. Dr. Lundberg previously served as President and Chief Executive Officer of Merus N.V. (formerly, Nasdaq: MRUS), a biotechnology company, from December 2019 until Merus was acquired by Genmab A/S in December 2025, and as the Principal Financial Officer of Merus from December 2019 to June 2023. Dr. Lundberg also served as a member of the board of directors of Merus from June 2019 to December 2025. Prior to joining Merus, he served as Chief Scientific Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biotechnology company, from January 2015 to February 2018. From February 2011 to January 2015, Dr. Lundberg served as Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company. Prior to that, he served as Director and Chief Medical Officer of Taligen Therapeutics, Inc., a biotechnology company acquired by Alexion in 2011. Dr. Lundberg held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus Pharmaceuticals, Inc. (acquired by Antisoma plc), Wyeth (acquired by Pfizer Inc.), and Genzyme Corporation (formerly, Nasdaq: GENZ). Dr. Lundberg has served as a member of the board of directors of Q32 Bio Inc. (Nasdaq: QTTB) since September 2017 and previously served on the board of directors of Vor Biopharma Inc. (Nasdaq: VOR) from July 2019 to July 2025. Dr. Lundberg received his M.D. from Stanford University and his M.B.A. from the University of Massachusetts. He completed post doctoral training at the Whitehead Institute/MIT and clinical training in Medicine and Medical Oncology at Harvard Medical School and the Dana Farber Cancer Institute.
- Peter Silverman
-
Peter Silverman自2026年4月起担任Yarrow董事会成员。Silverman先生此前曾在2023年1月至2025年12月被Genmab A/S收购之前，担任生物技术公司Merus N.V.（前身为纳斯达克：TERM3）的首席运营官。在担任首席运营官之前，Silverman先生曾在Merus担任多个领导职务，包括2020年4月至2023年1月的乌得勒支负责人、2018年2月至2025年12月的总法律顾问以及2017年2月至2018年2月的首席知识产权官兼美国法律部负责人。在加入Merus之前，Silverman先生是国际律师事务所Kirkland & Ellis LLP的合伙人，在那里他代表了众多生命科学公司，涉及一系列法律事务和技术。此前，Silverman先生是Kaye Scholer LLP（现为Arnold & Porter Kaye Scholer LLP）的合伙人，在此之前，Silverman先生还曾担任美国新泽西州地区法院法官Anne E. Thompson的司法法律书记员。他拥有福特汉姆大学法学院法学博士学位和罗切斯特大学生物学学士学位。
Peter Silverman has served as a member of Yarrow's board of directors since April 2026. Mr. Silverman previously served as Chief Operating Officer of Merus N.V. (formerly, Nasdaq: MRUS), a biotechnology company, from January 2023 until its acquisition by Genmab A/S in December 2025. Prior to serving as Chief Operating Officer, Mr. Silverman held several leadership roles at Merus, including Head of Utrecht from April 2020 to January 2023, General Counsel from February 2018 to December 2025, and Chief Intellectual Property Officer and Head of U.S. Legal from February 2017 to February 2018. Before joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, an international law firm, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Previously, Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law and a B.A. in biology from the University of Rochester. - Peter Silverman自2026年4月起担任Yarrow董事会成员。Silverman先生此前曾在2023年1月至2025年12月被Genmab A/S收购之前，担任生物技术公司Merus N.V.（前身为纳斯达克：TERM3）的首席运营官。在担任首席运营官之前，Silverman先生曾在Merus担任多个领导职务，包括2020年4月至2023年1月的乌得勒支负责人、2018年2月至2025年12月的总法律顾问以及2017年2月至2018年2月的首席知识产权官兼美国法律部负责人。在加入Merus之前，Silverman先生是国际律师事务所Kirkland & Ellis LLP的合伙人，在那里他代表了众多生命科学公司，涉及一系列法律事务和技术。此前，Silverman先生是Kaye Scholer LLP（现为Arnold & Porter Kaye Scholer LLP）的合伙人，在此之前，Silverman先生还曾担任美国新泽西州地区法院法官Anne E. Thompson的司法法律书记员。他拥有福特汉姆大学法学院法学博士学位和罗切斯特大学生物学学士学位。
- Peter Silverman has served as a member of Yarrow's board of directors since April 2026. Mr. Silverman previously served as Chief Operating Officer of Merus N.V. (formerly, Nasdaq: MRUS), a biotechnology company, from January 2023 until its acquisition by Genmab A/S in December 2025. Prior to serving as Chief Operating Officer, Mr. Silverman held several leadership roles at Merus, including Head of Utrecht from April 2020 to January 2023, General Counsel from February 2018 to December 2025, and Chief Intellectual Property Officer and Head of U.S. Legal from February 2017 to February 2018. Before joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, an international law firm, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Previously, Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law and a B.A. in biology from the University of Rochester.
- Rebecca Frey
-
Rebecca Frey自2025年10月起担任Yarrow首席执行官兼总裁，自2025年12月起担任Yarrow董事会成员。根据《亚罗宪章》，她当选为在任董事。在加入Yarrow之前，Frey女士于2025年2月至2026年1月在领先的生命科学投资公司RTW担任风险合伙人，并于2021年2月至2025年12月在Elm Street Ventures担任风险合伙人。Frey女士还在2025年2月至2025年7月期间担任生物技术公司Prolium Bioscience的临时首席执行官。在加入RTW之前，Frey女士曾于2021年4月至2024年5月担任生物技术公司Siduma Therapeutics的首席执行官，于2020年2月至2021年12月担任生物技术公司EvolveImmune Therapeutics，Inc.的首席运营官，于2018年至2020年担任生物技术公司Cardurion Pharmaceuticals，Inc.的首席运营官，并于2017年至2018年担任生物技术公司Prevail Therapeutics Inc.（前身为纳斯达克：PRVL）的运营执行副总裁。在加入Prevail之前，Frey女士于2006年10月至2017年9月在生物制药公司亚力兄制药公司（前身为纳斯达克：ALXN）担任过各种运营领导职务。在任职于亚力兄制药之前，Frey女士曾在诺华制药从事开发和医疗事务工作，并且是东北大学的助理教授。弗雷女士目前担任生物技术公司Octant Bio的董事会成员。Frey女士此前曾于2024年8月至2025年12月担任Artelis Biopharma的执行主席，并在Halda Therapeutics的董事会任职，任期自2019年至2025年被强生收购。Frey女士于2023年8月至2025年2月期间担任501c（3）非营利组织Latinos in Bio的董事。Frey女士拥有东北大学药学博士学位，并在东北大学和塔夫茨医学中心完成了博士后临床研究奖学金。弗雷女士还拥有麻省理工学院斯隆管理学院的管理和领导力高管证书。Frey女士是由美国国家公司董事协会（NACD.DC）认证的董事职位。
Rebecca Frey has served as Yarrow's Chief Executive Officer and President since October 2025 and as a member of the Yarrow board of directors since December 2025. She was elected as an At Large Director in accordance with the Yarrow Charter. Prior to joining Yarrow, Ms. Frey served as a Venture Partner at RTW, a leading life sciences investment firm, from February 2025 to January 2026 and served as a Venture Partner at Elm Street Ventures from February 2021 to December 2025. Ms. Frey also served as the interim Chief Executive Officer of Prolium Bioscience, a biotechnology company, from February 2025 to July 2025. Prior to joining RTW, Ms. Frey served as Chief Executive Officer of Siduma Therapeutics, a biotechnology company, from April 2021 to May 2024, Chief Operating Officer at EvolveImmune Therapeutics, Inc., a biotechnology company, from February 2020 to December 2021, Chief Operating Officer at Cardurion Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020, and Executive Vice President of Operations at Prevail Therapeutics Inc. (formerly, Nasdaq: PRVL), a biotechnology company, from 2017 to 2018. Prior to joining Prevail, Ms. Frey held various operational leadership roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from October 2006 to September 2017. Prior to her service at Alexion Pharmaceuticals, Ms. Frey worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University. Ms. Frey currently serves on the board of Octant Bio, a biotechnology company. Ms. Frey previously served as Executive Chair of Artelis Biopharma from August 2024 to December 2025 and served on the board of directors of Halda Therapeutics, from 2019 until it was acquired by Johnson & Johnson in 2025. Ms. Frey served as a director of Latinos in Bio, a 501c(3) nonprofit organization, from August 2023 to February 2025. Ms. Frey holds a Doctor of Pharmacy degree from Northeastern University and completed a post doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. Ms. Frey also holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management. Ms. Frey is Directorship Certified by the National Association of Corporate Directors (NACD.DC). - Rebecca Frey自2025年10月起担任Yarrow首席执行官兼总裁，自2025年12月起担任Yarrow董事会成员。根据《亚罗宪章》，她当选为在任董事。在加入Yarrow之前，Frey女士于2025年2月至2026年1月在领先的生命科学投资公司RTW担任风险合伙人，并于2021年2月至2025年12月在Elm Street Ventures担任风险合伙人。Frey女士还在2025年2月至2025年7月期间担任生物技术公司Prolium Bioscience的临时首席执行官。在加入RTW之前，Frey女士曾于2021年4月至2024年5月担任生物技术公司Siduma Therapeutics的首席执行官，于2020年2月至2021年12月担任生物技术公司EvolveImmune Therapeutics，Inc.的首席运营官，于2018年至2020年担任生物技术公司Cardurion Pharmaceuticals，Inc.的首席运营官，并于2017年至2018年担任生物技术公司Prevail Therapeutics Inc.（前身为纳斯达克：PRVL）的运营执行副总裁。在加入Prevail之前，Frey女士于2006年10月至2017年9月在生物制药公司亚力兄制药公司（前身为纳斯达克：ALXN）担任过各种运营领导职务。在任职于亚力兄制药之前，Frey女士曾在诺华制药从事开发和医疗事务工作，并且是东北大学的助理教授。弗雷女士目前担任生物技术公司Octant Bio的董事会成员。Frey女士此前曾于2024年8月至2025年12月担任Artelis Biopharma的执行主席，并在Halda Therapeutics的董事会任职，任期自2019年至2025年被强生收购。Frey女士于2023年8月至2025年2月期间担任501c（3）非营利组织Latinos in Bio的董事。Frey女士拥有东北大学药学博士学位，并在东北大学和塔夫茨医学中心完成了博士后临床研究奖学金。弗雷女士还拥有麻省理工学院斯隆管理学院的管理和领导力高管证书。Frey女士是由美国国家公司董事协会（NACD.DC）认证的董事职位。
- Rebecca Frey has served as Yarrow's Chief Executive Officer and President since October 2025 and as a member of the Yarrow board of directors since December 2025. She was elected as an At Large Director in accordance with the Yarrow Charter. Prior to joining Yarrow, Ms. Frey served as a Venture Partner at RTW, a leading life sciences investment firm, from February 2025 to January 2026 and served as a Venture Partner at Elm Street Ventures from February 2021 to December 2025. Ms. Frey also served as the interim Chief Executive Officer of Prolium Bioscience, a biotechnology company, from February 2025 to July 2025. Prior to joining RTW, Ms. Frey served as Chief Executive Officer of Siduma Therapeutics, a biotechnology company, from April 2021 to May 2024, Chief Operating Officer at EvolveImmune Therapeutics, Inc., a biotechnology company, from February 2020 to December 2021, Chief Operating Officer at Cardurion Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020, and Executive Vice President of Operations at Prevail Therapeutics Inc. (formerly, Nasdaq: PRVL), a biotechnology company, from 2017 to 2018. Prior to joining Prevail, Ms. Frey held various operational leadership roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from October 2006 to September 2017. Prior to her service at Alexion Pharmaceuticals, Ms. Frey worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University. Ms. Frey currently serves on the board of Octant Bio, a biotechnology company. Ms. Frey previously served as Executive Chair of Artelis Biopharma from August 2024 to December 2025 and served on the board of directors of Halda Therapeutics, from 2019 until it was acquired by Johnson & Johnson in 2025. Ms. Frey served as a director of Latinos in Bio, a 501c(3) nonprofit organization, from August 2023 to February 2025. Ms. Frey holds a Doctor of Pharmacy degree from Northeastern University and completed a post doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. Ms. Frey also holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management. Ms. Frey is Directorship Certified by the National Association of Corporate Directors (NACD.DC).
- Steven Hoerter
-
2011年8月以来，Steven L. Hoerter担任商业高级副总裁。从2010年到2011年，他担任Hoffmann-LaRoche总经理及管理中心负责人，负责非洲撒哈拉以南和印度洋地区，位于南非约翰内斯堡。从2005年到2010年，他在Genentech担任多种职位，包括带领高级领导团队，担任Genentech公司的BioOncology业务高级董事，负责管道开发和商业运作。之前，他在喀戎公司和礼来公司任职。他在礼来公司Hoerter任职 11年，他负责美国、欧洲和非洲的销售、业务发展、市场营销和业务单元管理。他拥有巴克内尔大学俄罗斯与政治学学士学位，蒂尔堡大学MBA学位和普渡大学管理学硕士学位。
Steven Hoerter has served as a member of Yarrow's board of directors since April 2026. Mr. Hoerter served as President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. (formerly, Nasdaq: DCPH), a biopharmaceutical company, from March 2019 to June 2024, when Deciphera was acquired by ONO Pharmaceutical. He also served as a member of the board of directors of Deciphera from May 2018 to June 2024. Prior to Deciphera, he served as Chief Commercial Officer of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a biotechnology company, from February 2016 to March 2019. From August 2011 to March 2015, Mr. Hoerter served as Senior Vice President, Commercial at Clovis Oncology, Inc., a biotechnology company, and from March 2015 to February 2016, he served as Chief Commercial Officer. Prior to that, he held roles of increasing responsibility at F. Hoffman La Roche, AG, Genentech, Inc. (acquired by Roche), Chiron Corporation (acquired by Novartis AG) and Eli Lilly and Company. Mr. Hoerter has served as a member of the board of directors of ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) since August 2021, C4 Therapeutics, Inc. (Nasdaq: CCCC) since November 2024 and MBX Biosciences, Inc. (Nasdaq: MBX) since April 2025. Mr. Hoerter previously served on the board of directors of Constellation Pharmaceuticals, Inc. (formerly, Nasdaq: CNST) from September 2018 until it was acquired by MorphoSys AG in July 2021 and Ignyta, Inc. (formerly, Nasdaq: RXDX) from December 2016 until it was acquired by Roche in February 2018. Mr. Hoerter received his B.A. from Bucknell University, his M.B.A. from Tilburg University and his M.S. in management from Purdue University. - 2011年8月以来，Steven L. Hoerter担任商业高级副总裁。从2010年到2011年，他担任Hoffmann-LaRoche总经理及管理中心负责人，负责非洲撒哈拉以南和印度洋地区，位于南非约翰内斯堡。从2005年到2010年，他在Genentech担任多种职位，包括带领高级领导团队，担任Genentech公司的BioOncology业务高级董事，负责管道开发和商业运作。之前，他在喀戎公司和礼来公司任职。他在礼来公司Hoerter任职 11年，他负责美国、欧洲和非洲的销售、业务发展、市场营销和业务单元管理。他拥有巴克内尔大学俄罗斯与政治学学士学位，蒂尔堡大学MBA学位和普渡大学管理学硕士学位。
- Steven Hoerter has served as a member of Yarrow's board of directors since April 2026. Mr. Hoerter served as President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. (formerly, Nasdaq: DCPH), a biopharmaceutical company, from March 2019 to June 2024, when Deciphera was acquired by ONO Pharmaceutical. He also served as a member of the board of directors of Deciphera from May 2018 to June 2024. Prior to Deciphera, he served as Chief Commercial Officer of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a biotechnology company, from February 2016 to March 2019. From August 2011 to March 2015, Mr. Hoerter served as Senior Vice President, Commercial at Clovis Oncology, Inc., a biotechnology company, and from March 2015 to February 2016, he served as Chief Commercial Officer. Prior to that, he held roles of increasing responsibility at F. Hoffman La Roche, AG, Genentech, Inc. (acquired by Roche), Chiron Corporation (acquired by Novartis AG) and Eli Lilly and Company. Mr. Hoerter has served as a member of the board of directors of ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) since August 2021, C4 Therapeutics, Inc. (Nasdaq: CCCC) since November 2024 and MBX Biosciences, Inc. (Nasdaq: MBX) since April 2025. Mr. Hoerter previously served on the board of directors of Constellation Pharmaceuticals, Inc. (formerly, Nasdaq: CNST) from September 2018 until it was acquired by MorphoSys AG in July 2021 and Ignyta, Inc. (formerly, Nasdaq: RXDX) from December 2016 until it was acquired by Roche in February 2018. Mr. Hoerter received his B.A. from Bucknell University, his M.B.A. from Tilburg University and his M.S. in management from Purdue University.
高管简历
中英对照 | 中文 | 英文- Steven Ryder
Steven Ryder自2019年1月起担任RallyBio的首席医疗官。此前，Ryder博士从2013年7月到2018年12月担任Alexion的首席发展官。从2008年4月到2013年4月，Ryder博士担任Astellas Inc.或Astellas的Astellas Pharma全球开发总裁。在加入Astellas之前，Ryder博士在Pfizer工作了21年，在那里他担任越来越多的职务，包括全球临床开发主管。赖德博士在西奈山的伊坎医学院获得了医学博士学位。
Steven Ryder has served as Yarrow's Chief Medical Officer since April 2026. Prior to joining Yarrow, Dr. Ryder served as Chief Medical Officer of Rallybio Corp. (Nasdaq: RLYB), a biotechnology company, from December 2018 to March 2026, where he was responsible for leading the company's clinical development and medical strategy. Prior to Rallybio, Dr. Ryder served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from July 2013 to December 2018, where he led the global development, registration, and approval of new drug candidates for rare diseases and contributed to the overall growth of the company. Previously, he was the founding President of Astellas Pharma Global Development and spent 21 years in development at Pfizer. Dr. Ryder currently serves on the board of directors of MBX Biosciences, Inc. and Gaylord Specialty Healthcare. He received his M.D. from the Icahn School of Medicine at Mount Sinai.- Steven Ryder自2019年1月起担任RallyBio的首席医疗官。此前，Ryder博士从2013年7月到2018年12月担任Alexion的首席发展官。从2008年4月到2013年4月，Ryder博士担任Astellas Inc.或Astellas的Astellas Pharma全球开发总裁。在加入Astellas之前，Ryder博士在Pfizer工作了21年，在那里他担任越来越多的职务，包括全球临床开发主管。赖德博士在西奈山的伊坎医学院获得了医学博士学位。
- Steven Ryder has served as Yarrow's Chief Medical Officer since April 2026. Prior to joining Yarrow, Dr. Ryder served as Chief Medical Officer of Rallybio Corp. (Nasdaq: RLYB), a biotechnology company, from December 2018 to March 2026, where he was responsible for leading the company's clinical development and medical strategy. Prior to Rallybio, Dr. Ryder served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from July 2013 to December 2018, where he led the global development, registration, and approval of new drug candidates for rare diseases and contributed to the overall growth of the company. Previously, he was the founding President of Astellas Pharma Global Development and spent 21 years in development at Pfizer. Dr. Ryder currently serves on the board of directors of MBX Biosciences, Inc. and Gaylord Specialty Healthcare. He received his M.D. from the Icahn School of Medicine at Mount Sinai.
- Tyler Zeronda
Tyler Zeronda于2022年3月被任命为公司首席财务官兼财务主管，此前自2021年6月起担任临时首席财务官兼财务主管。Zeronda先生此前曾担任公司的财务副总裁，从关闭之日起直到他被任命为临时CFO。Zeronda先生于2019年4月加入Foamix，负责与VYNE的商业运营，财务规划，财务，风险管理和供应链事务相关的所有财务活动。从2013年4月至2019年4月，Zeronda先生在纳斯达克上市公司Aerie Pharmaceuticals Inc."Aerie”；担任越来越多的财务职务，最终担任财务总监。在Aerie任职期间，Zeronda先生支持公司的IPO，并帮助领导他的部门’；的成长和转型，从一个IPO前、开发阶段的实体转变为一个支持多种药物上市的完全集成的商业金融组织。加入Aerie公司之前，他曾任职Ernst&Young公司，在那里他曾专注于医疗保健行业的保证服务。Zeronda先生在弗吉尼亚大学获得会计学硕士学位，在拉斐特学院获得经济学和商业文学学士学位，并且是一名注册会计师。
Tyler Zeronda is expected to serve as Yarrow's Chief Financial Officer upon the closing of the Merger. Mr. Zeronda served as Chief Financial Officer and Treasurer of VYNE Therapeutics Inc. (Nasdaq: VYNE), a biopharmaceutical company, since March 2022 and previously served as VYNE's Interim Chief Financial Officer and Treasurer from June 2021 to March 2022. Mr. Zeronda previously served as Vice President of Finance of VYNE from March 2020 to June 2021 and as Vice President of Finance of Foamix Pharmaceuticals Ltd. (formerly, Nasdaq: FOMX), a pharmaceutical company, from April 2019 until its merger with VYNE in March 2020, where he helped lead the buildout of the company's finance department in the U.S. and was responsible for financial planning, commercial finance and supply chain. From April 2013 until April 2019, Mr. Zeronda held positions across corporate and operational finance at Aerie Pharmaceuticals Inc. (formerly, Nasdaq: AERI), a pharmaceutical company, where he helped the company scale and transition from a pre IPO, clinical stage company to a commercial stage public company. Mr. Zeronda began his career at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his Master of Science in accounting from the University of Virginia, holds a Bachelor of Arts with a double major in economics and business and history from Lafayette College and is a licensed CPA.- Tyler Zeronda于2022年3月被任命为公司首席财务官兼财务主管，此前自2021年6月起担任临时首席财务官兼财务主管。Zeronda先生此前曾担任公司的财务副总裁，从关闭之日起直到他被任命为临时CFO。Zeronda先生于2019年4月加入Foamix，负责与VYNE的商业运营，财务规划，财务，风险管理和供应链事务相关的所有财务活动。从2013年4月至2019年4月，Zeronda先生在纳斯达克上市公司Aerie Pharmaceuticals Inc."Aerie”；担任越来越多的财务职务，最终担任财务总监。在Aerie任职期间，Zeronda先生支持公司的IPO，并帮助领导他的部门’；的成长和转型，从一个IPO前、开发阶段的实体转变为一个支持多种药物上市的完全集成的商业金融组织。加入Aerie公司之前，他曾任职Ernst&Young公司，在那里他曾专注于医疗保健行业的保证服务。Zeronda先生在弗吉尼亚大学获得会计学硕士学位，在拉斐特学院获得经济学和商业文学学士学位，并且是一名注册会计师。
- Tyler Zeronda is expected to serve as Yarrow's Chief Financial Officer upon the closing of the Merger. Mr. Zeronda served as Chief Financial Officer and Treasurer of VYNE Therapeutics Inc. (Nasdaq: VYNE), a biopharmaceutical company, since March 2022 and previously served as VYNE's Interim Chief Financial Officer and Treasurer from June 2021 to March 2022. Mr. Zeronda previously served as Vice President of Finance of VYNE from March 2020 to June 2021 and as Vice President of Finance of Foamix Pharmaceuticals Ltd. (formerly, Nasdaq: FOMX), a pharmaceutical company, from April 2019 until its merger with VYNE in March 2020, where he helped lead the buildout of the company's finance department in the U.S. and was responsible for financial planning, commercial finance and supply chain. From April 2013 until April 2019, Mr. Zeronda held positions across corporate and operational finance at Aerie Pharmaceuticals Inc. (formerly, Nasdaq: AERI), a pharmaceutical company, where he helped the company scale and transition from a pre IPO, clinical stage company to a commercial stage public company. Mr. Zeronda began his career at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his Master of Science in accounting from the University of Virginia, holds a Bachelor of Arts with a double major in economics and business and history from Lafayette College and is a licensed CPA.
- Rebecca Frey
Rebecca Frey自2025年10月起担任Yarrow首席执行官兼总裁，自2025年12月起担任Yarrow董事会成员。根据《亚罗宪章》，她当选为在任董事。在加入Yarrow之前，Frey女士于2025年2月至2026年1月在领先的生命科学投资公司RTW担任风险合伙人，并于2021年2月至2025年12月在Elm Street Ventures担任风险合伙人。Frey女士还在2025年2月至2025年7月期间担任生物技术公司Prolium Bioscience的临时首席执行官。在加入RTW之前，Frey女士曾于2021年4月至2024年5月担任生物技术公司Siduma Therapeutics的首席执行官，于2020年2月至2021年12月担任生物技术公司EvolveImmune Therapeutics，Inc.的首席运营官，于2018年至2020年担任生物技术公司Cardurion Pharmaceuticals，Inc.的首席运营官，并于2017年至2018年担任生物技术公司Prevail Therapeutics Inc.（前身为纳斯达克：PRVL）的运营执行副总裁。在加入Prevail之前，Frey女士于2006年10月至2017年9月在生物制药公司亚力兄制药公司（前身为纳斯达克：ALXN）担任过各种运营领导职务。在任职于亚力兄制药之前，Frey女士曾在诺华制药从事开发和医疗事务工作，并且是东北大学的助理教授。弗雷女士目前担任生物技术公司Octant Bio的董事会成员。Frey女士此前曾于2024年8月至2025年12月担任Artelis Biopharma的执行主席，并在Halda Therapeutics的董事会任职，任期自2019年至2025年被强生收购。Frey女士于2023年8月至2025年2月期间担任501c（3）非营利组织Latinos in Bio的董事。Frey女士拥有东北大学药学博士学位，并在东北大学和塔夫茨医学中心完成了博士后临床研究奖学金。弗雷女士还拥有麻省理工学院斯隆管理学院的管理和领导力高管证书。Frey女士是由美国国家公司董事协会（NACD.DC）认证的董事职位。
Rebecca Frey has served as Yarrow's Chief Executive Officer and President since October 2025 and as a member of the Yarrow board of directors since December 2025. She was elected as an At Large Director in accordance with the Yarrow Charter. Prior to joining Yarrow, Ms. Frey served as a Venture Partner at RTW, a leading life sciences investment firm, from February 2025 to January 2026 and served as a Venture Partner at Elm Street Ventures from February 2021 to December 2025. Ms. Frey also served as the interim Chief Executive Officer of Prolium Bioscience, a biotechnology company, from February 2025 to July 2025. Prior to joining RTW, Ms. Frey served as Chief Executive Officer of Siduma Therapeutics, a biotechnology company, from April 2021 to May 2024, Chief Operating Officer at EvolveImmune Therapeutics, Inc., a biotechnology company, from February 2020 to December 2021, Chief Operating Officer at Cardurion Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020, and Executive Vice President of Operations at Prevail Therapeutics Inc. (formerly, Nasdaq: PRVL), a biotechnology company, from 2017 to 2018. Prior to joining Prevail, Ms. Frey held various operational leadership roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from October 2006 to September 2017. Prior to her service at Alexion Pharmaceuticals, Ms. Frey worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University. Ms. Frey currently serves on the board of Octant Bio, a biotechnology company. Ms. Frey previously served as Executive Chair of Artelis Biopharma from August 2024 to December 2025 and served on the board of directors of Halda Therapeutics, from 2019 until it was acquired by Johnson & Johnson in 2025. Ms. Frey served as a director of Latinos in Bio, a 501c(3) nonprofit organization, from August 2023 to February 2025. Ms. Frey holds a Doctor of Pharmacy degree from Northeastern University and completed a post doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. Ms. Frey also holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management. Ms. Frey is Directorship Certified by the National Association of Corporate Directors (NACD.DC).- Rebecca Frey自2025年10月起担任Yarrow首席执行官兼总裁，自2025年12月起担任Yarrow董事会成员。根据《亚罗宪章》，她当选为在任董事。在加入Yarrow之前，Frey女士于2025年2月至2026年1月在领先的生命科学投资公司RTW担任风险合伙人，并于2021年2月至2025年12月在Elm Street Ventures担任风险合伙人。Frey女士还在2025年2月至2025年7月期间担任生物技术公司Prolium Bioscience的临时首席执行官。在加入RTW之前，Frey女士曾于2021年4月至2024年5月担任生物技术公司Siduma Therapeutics的首席执行官，于2020年2月至2021年12月担任生物技术公司EvolveImmune Therapeutics，Inc.的首席运营官，于2018年至2020年担任生物技术公司Cardurion Pharmaceuticals，Inc.的首席运营官，并于2017年至2018年担任生物技术公司Prevail Therapeutics Inc.（前身为纳斯达克：PRVL）的运营执行副总裁。在加入Prevail之前，Frey女士于2006年10月至2017年9月在生物制药公司亚力兄制药公司（前身为纳斯达克：ALXN）担任过各种运营领导职务。在任职于亚力兄制药之前，Frey女士曾在诺华制药从事开发和医疗事务工作，并且是东北大学的助理教授。弗雷女士目前担任生物技术公司Octant Bio的董事会成员。Frey女士此前曾于2024年8月至2025年12月担任Artelis Biopharma的执行主席，并在Halda Therapeutics的董事会任职，任期自2019年至2025年被强生收购。Frey女士于2023年8月至2025年2月期间担任501c（3）非营利组织Latinos in Bio的董事。Frey女士拥有东北大学药学博士学位，并在东北大学和塔夫茨医学中心完成了博士后临床研究奖学金。弗雷女士还拥有麻省理工学院斯隆管理学院的管理和领导力高管证书。Frey女士是由美国国家公司董事协会（NACD.DC）认证的董事职位。
- Rebecca Frey has served as Yarrow's Chief Executive Officer and President since October 2025 and as a member of the Yarrow board of directors since December 2025. She was elected as an At Large Director in accordance with the Yarrow Charter. Prior to joining Yarrow, Ms. Frey served as a Venture Partner at RTW, a leading life sciences investment firm, from February 2025 to January 2026 and served as a Venture Partner at Elm Street Ventures from February 2021 to December 2025. Ms. Frey also served as the interim Chief Executive Officer of Prolium Bioscience, a biotechnology company, from February 2025 to July 2025. Prior to joining RTW, Ms. Frey served as Chief Executive Officer of Siduma Therapeutics, a biotechnology company, from April 2021 to May 2024, Chief Operating Officer at EvolveImmune Therapeutics, Inc., a biotechnology company, from February 2020 to December 2021, Chief Operating Officer at Cardurion Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020, and Executive Vice President of Operations at Prevail Therapeutics Inc. (formerly, Nasdaq: PRVL), a biotechnology company, from 2017 to 2018. Prior to joining Prevail, Ms. Frey held various operational leadership roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from October 2006 to September 2017. Prior to her service at Alexion Pharmaceuticals, Ms. Frey worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University. Ms. Frey currently serves on the board of Octant Bio, a biotechnology company. Ms. Frey previously served as Executive Chair of Artelis Biopharma from August 2024 to December 2025 and served on the board of directors of Halda Therapeutics, from 2019 until it was acquired by Johnson & Johnson in 2025. Ms. Frey served as a director of Latinos in Bio, a 501c(3) nonprofit organization, from August 2023 to February 2025. Ms. Frey holds a Doctor of Pharmacy degree from Northeastern University and completed a post doctoral clinical research fellowship at Northeastern University and Tufts Medical Center. Ms. Frey also holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management. Ms. Frey is Directorship Certified by the National Association of Corporate Directors (NACD.DC).
- Rachael Alford
Rachael Alford自2026年1月起担任Yarrow的首席运营官。在加入Yarrow之前，Alford博士曾于2020年5月至2026年1月期间在生物技术公司Rallybio Corp（纳斯达克：RLYB）担任化学、制造和控制主管，负责领导该公司候选药物的制造工艺的战略、开发和监督。在加入Rallybio之前，Alford博士曾于2004年11月至2020年5月在生物制药公司亚力兄制药公司（前身为TERM1：ALXN）担任多个运营和开发职务，包括生化工艺开发高级总监和全球工艺开发副总裁。Alford博士在伦敦帝国理工学院获得化学学士学位和生物物理化学博士学位，是耶鲁大学的博士后研究助理。
Rachael Alford has served as Yarrow's Chief Operating Officer since January 2026. Prior to joining Yarrow, Dr. Alford served as Head of Chemistry, Manufacturing and Controls at Rallybio Corp (Nasdaq: RLYB), a biotechnology company, from May 2020 to January 2026, where she was responsible for leading the strategy, development and oversight of manufacturing processes for the company's drug candidates. Prior to joining Rallybio, Dr. Alford held various operational and developmental roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from November 2004 to May 2020, including Senior Director, Biochemical Process Development, and Vice President of Global Process Development. Dr. Alford received her B.S. in Chemistry and Ph.D. in Biophysical Chemistry from Imperial College London and was a postdoctoral research associate at Yale University.- Rachael Alford自2026年1月起担任Yarrow的首席运营官。在加入Yarrow之前，Alford博士曾于2020年5月至2026年1月期间在生物技术公司Rallybio Corp（纳斯达克：RLYB）担任化学、制造和控制主管，负责领导该公司候选药物的制造工艺的战略、开发和监督。在加入Rallybio之前，Alford博士曾于2004年11月至2020年5月在生物制药公司亚力兄制药公司（前身为TERM1：ALXN）担任多个运营和开发职务，包括生化工艺开发高级总监和全球工艺开发副总裁。Alford博士在伦敦帝国理工学院获得化学学士学位和生物物理化学博士学位，是耶鲁大学的博士后研究助理。
- Rachael Alford has served as Yarrow's Chief Operating Officer since January 2026. Prior to joining Yarrow, Dr. Alford served as Head of Chemistry, Manufacturing and Controls at Rallybio Corp (Nasdaq: RLYB), a biotechnology company, from May 2020 to January 2026, where she was responsible for leading the strategy, development and oversight of manufacturing processes for the company's drug candidates. Prior to joining Rallybio, Dr. Alford held various operational and developmental roles at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN), a biopharmaceutical company, from November 2004 to May 2020, including Senior Director, Biochemical Process Development, and Vice President of Global Process Development. Dr. Alford received her B.S. in Chemistry and Ph.D. in Biophysical Chemistry from Imperial College London and was a postdoctoral research associate at Yale University.
- Lori Payton
Lori Payton自2026年1月起担任Yarrow的首席开发官。在加入Yarrow之前，Payton博士于2024年3月至2025年12月期间在管理咨询公司Harkness Consulting，LLC担任首席顾问和首席执行官，负责向多个生物科学客户提供战略规划和发展咨询，并于2022年2月至2024年1月期间在生物技术公司AlloVir，Inc.（前身为纳斯达克：ALVR）担任发展战略与运营高级副总裁，负责战略规划、临床运营、项目管理、生物识别和供应商管理职能。此外，佩顿博士是执行领导团队的成员，负责实现关键的发展里程碑。Payton博士还曾于2020年7月至2021年8月在Vista Life Innovations（一家为残疾个人提供项目和服务的非营利组织）担任战略和业务发展副总裁，于2019年4月至2020年6月在Sage Therapeutics（前身为纳斯达克：SAGE）担任公司战略、投资组合和项目管理高级副总裁，并于2014年8月至2019年3月在亚力兄制药公司（前身为丨纳斯达克纳斯达克：ALXN）担任副总裁兼全球发展团队负责人。Payton博士于1993年至2013年在辉瑞任职期间曾担任多个研发职位。Payton博士目前在Vista Life Innovations董事会的长期规划委员会任职。佩顿博士在马萨诸塞州惠顿学院获得生物学学士学位，在波士顿大学医学院获得药理学和实验治疗学博士学位。
Lori Payton has served as Yarrow's Chief Development Officer since January 2026. Prior to joining Yarrow, Dr. Payton served as Principal Consultant and Chief Executive Officer at Harkness Consulting, LLC, a management consulting firm, from March 2024 to December 2025, where she was responsible for strategic planning and development consulting to several bioscience clients, and served as Senior Vice President, Development Strategy & Operations at AlloVir, Inc. (formerly, Nasdaq: ALVR), a biotechnology company, from February 2022 to January 2024, where she was responsible for Strategic Planning, Clinical Operations, Program Management, Biometrics and Vendor Management functions. In addition, Dr Payton was a member of the executive leadership team and was accountable for achievement of critical development milestones. Dr. Payton also served as the Vice President of Strategy and Business Development at Vista Life Innovations, a nonprofit organization providing programs and services to individuals with disabilities, from July 2020 to August 2021, Senior Vice President, Corporate Strategy, Portfolio & Program Management at Sage Therapeutics (formerly, Nasdaq: SAGE) from April 2019 to June 2020 and Vice President, Global Development Team Leader at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN) from August 2014 to March 2019. Dr. Payton held several positions in Research and Development during her tenure at Pfizer from 1993 2013. Dr. Payton currently serves on the Long Term Planning Committee of the board of Vista Life Innovations. Dr. Payton received her B.A. in Biology from Wheaton College Massachusetts and her Ph.D. in Pharmacology & Experimental Therapeutics from Boston University School of Medicine.- Lori Payton自2026年1月起担任Yarrow的首席开发官。在加入Yarrow之前，Payton博士于2024年3月至2025年12月期间在管理咨询公司Harkness Consulting，LLC担任首席顾问和首席执行官，负责向多个生物科学客户提供战略规划和发展咨询，并于2022年2月至2024年1月期间在生物技术公司AlloVir，Inc.（前身为纳斯达克：ALVR）担任发展战略与运营高级副总裁，负责战略规划、临床运营、项目管理、生物识别和供应商管理职能。此外，佩顿博士是执行领导团队的成员，负责实现关键的发展里程碑。Payton博士还曾于2020年7月至2021年8月在Vista Life Innovations（一家为残疾个人提供项目和服务的非营利组织）担任战略和业务发展副总裁，于2019年4月至2020年6月在Sage Therapeutics（前身为纳斯达克：SAGE）担任公司战略、投资组合和项目管理高级副总裁，并于2014年8月至2019年3月在亚力兄制药公司（前身为丨纳斯达克纳斯达克：ALXN）担任副总裁兼全球发展团队负责人。Payton博士于1993年至2013年在辉瑞任职期间曾担任多个研发职位。Payton博士目前在Vista Life Innovations董事会的长期规划委员会任职。佩顿博士在马萨诸塞州惠顿学院获得生物学学士学位，在波士顿大学医学院获得药理学和实验治疗学博士学位。
- Lori Payton has served as Yarrow's Chief Development Officer since January 2026. Prior to joining Yarrow, Dr. Payton served as Principal Consultant and Chief Executive Officer at Harkness Consulting, LLC, a management consulting firm, from March 2024 to December 2025, where she was responsible for strategic planning and development consulting to several bioscience clients, and served as Senior Vice President, Development Strategy & Operations at AlloVir, Inc. (formerly, Nasdaq: ALVR), a biotechnology company, from February 2022 to January 2024, where she was responsible for Strategic Planning, Clinical Operations, Program Management, Biometrics and Vendor Management functions. In addition, Dr Payton was a member of the executive leadership team and was accountable for achievement of critical development milestones. Dr. Payton also served as the Vice President of Strategy and Business Development at Vista Life Innovations, a nonprofit organization providing programs and services to individuals with disabilities, from July 2020 to August 2021, Senior Vice President, Corporate Strategy, Portfolio & Program Management at Sage Therapeutics (formerly, Nasdaq: SAGE) from April 2019 to June 2020 and Vice President, Global Development Team Leader at Alexion Pharmaceuticals, Inc. (formerly, Nasdaq: ALXN) from August 2014 to March 2019. Dr. Payton held several positions in Research and Development during her tenure at Pfizer from 1993 2013. Dr. Payton currently serves on the Long Term Planning Committee of the board of Vista Life Innovations. Dr. Payton received her B.A. in Biology from Wheaton College Massachusetts and her Ph.D. in Pharmacology & Experimental Therapeutics from Boston University School of Medicine.